Integrated ADC Characterization: From Target Binding & Internalization to Payload Activity & Tumor Cell Killing

This application note describes an integrated ADC characterization workflow centered on PathHunter internalization assays and the KILR cytotoxicity platform, with SPR microscopy included as a complementary binding-confirmation tool. Using belantamab mafodotin, an anti-BCMA ADC, and gemtuzumab ozogamicin, an anti-CD33 ADC, as clinically relevant examples, the workflow demonstrates how receptor-mediated internalization, payload-dependent cytotoxicity, and Fc-mediated effector functions can be evaluated together. The integrated workflow yields a more complete functional profile of ADC activity across discovery, characterization, and lot-comparability testing.